Partnership in Medicine and Biostatistics as the basis for improving the curability of prostate cancer

Speaker: Dr. Anthony D’Amico

Harvard medical School

Anthony D’Amico is the Eleanor Theresa Walters Distinguished Chair, Chief of Genitourinary Radiation Oncology at Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Chair of the residency executive committee in the Harvard Radiation Oncology Program, and Advisory Dean and Head of career advising and mentorship at Harvard medical School.

Dr. D’Amico is an internationally known expert in the treatment of prostate cancer and has defined combined modality staging, which is used to select patients with localized prostate cancer for specific surgical or radiotheraputic treatment options.  He is the principal investigator of several federally funded grants that support his investigations in clinical trials that are aimed at defining future management strategies for men with prostate cancer.

Dr. D’Amico has been awarded the Best Doctor in America award annually since 2009 for his work in prostate cancer, the 2012 Harvard Medical School Arnold P. Gold Awardee for Humanism in Medicine, the HMS Faculty Mentoring and Teaching Award in 2014, 2015 and 2017, and the recipient of the Harvard Medical School Class of 2014, 2015 Career Advising and Mentoring Faculty Teaching Award in addition to the 2015-2016 Morton M. Kligerman Award provided by the Hospital of the University of PA. In December of 2016 his editorial on a landmark prostate cancer study in the New England Journal of Medicine was cited in The New Yorker as one of the most notable medical findings in 2016. In 2019 he was awarded the Grant V Rodkey, MD Award for Outstanding Contributions to Medical Education.